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The following Essay is part of a research program supported by 
the China Law Society Foundation (Program No. CLS(2011)D42), 
and presented at the Oregon Review of International Law’s 
Symposium China’s Role in Regulating the Global Information 
Economy. The assertions are based on Dr. Zhang’s many years of 
work in the field of Chinese Intellectual Property; however, citation is 
provided where necessary or helpful. 
INTRODUCTION 
In March of 2011, the Chinese Central Government State Council 
rolled out the Twelfth Five-Year Plan (Plan),1 which aims to establish 
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a sound protection system for International Patent Regulation (IPRs) 
for Traditional Chinese Medicine (TCM). The Plan stresses that the 
strengthening of Traditional Chinese Medicine Protection (TCMP) 
would have a positive social impact on China. 
Five years ago in 2006, the rumor of “abolishing TCM” was 
denounced by the Ministry of Health and the National Chinese 
Medicine Administrative Bureau.2 Moreover, China’s State Council 
issued “China 2009–2011 Deepened Medicine Health Organizational 
Reform Implementation Plan” (New Medicine Reform Plan) in 
January 20, 2009. This plan emphasized a more nationally 
government-guided support of TCM.3 
However, although inconsistent with these government policies of 
support and protection, TCM practice remains largely unprotected. As 
of 2011, lack of protection has become a serious problem. On the one 
hand, when those who practice Chinese medicine attempt to protect 
their new treatment methods and medicines, the first choice is not 
patenting, but by protecting certain methods with commercial and 
administrative security. On the other hand, scientific researchers have 
spent more time publishing their updated papers, rather than spending 
time applying for appropriate patents. 
With a history of 2000 to 3000 years, TCM has formed a unique 
system to diagnose and cure illness. However, the development of 
Chinese medicine and its patents is very slow when compared to 
modern Western plant-based medicines as biological drugs. With 
large drug companies making increasingly large amounts of money 
off of patents, the pressure to patent and protect medical technology 
has increased worldwide, and global competition in the Chinese 
medicine market has also intensified. Overseas drug manufacturing 
enterprises have increased efforts to appropriate TCMP. At present, 
with the exception of China, the top countries applying for TCMP are: 
 
1 China has recently decided to establish a protection system for traditional knowledge. 
Supporting the collation and passing down of traditional knowledge furthers the 
development of such a protection system. A coordinated mechanism for administration, 
protection, and utilization of Intellectual Property Rights (IPRs) for traditional medicine 
needs to be improved. See China’s Outline of 12th Five-Year Plan, Mar. 5, 2011, 
http://politics.people.com.cn/GB/1026/14159537.html) (last visited on Oct. 4, 2011) 
[hereinafter 11th Five Year Plan]. 
2 TCM Faces Homegrown Challenges, CHINA INTERNET INFO. CENTER, Aug. 27, 2008, 
http://www.china.org.cn/health/2008-08/27/content_16343759 .htm. 
3 See New Medical Reform Program Overview, NEW CHINA NEWS AGENCY, Apr. 8, 
2009, http://politics.people.com.cn/GB/1025/9090406.html. 
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Japan, South Korea, United States, and Germany. Surprisingly, the 
United States has leaped to third place during the past five years.4 
Before China’s entrance into the WTO, the lack of patents for 
Chinese medicine and new technology did not cause much economic 
loss. However, after China joined the WTO on November 10, 2001, 
the economic loss to China due to the plant medicine patent war has 
been a crushing blow to domestic Chinese TCM enterprises. Thus, the 
race to properly patent Chinese medicine throughout the world has 
become a hot-button topic. 
In respect to the patent wars and global race to patent TCM, a 
series of investigations on TCMP development has been conducted by 
both the Chinese government and scholars, and the author has 
reviewed the relevant legal flaws in China. Inevitably, the patent war 
for TCM has attracted global attention. The author’s research focus is 
on whether a reasonable solution would be to lower the patent 
standards particular to TCM. 
I 
LEGAL PERSPECTIVES OF TCMP: NEW SHACKLES 
Given the ancient origins of TCM, it is difficult to identify the 
exact source of the medical practice. Traditional cures are found in 
ancient books, such as “Shen Nong Ben Cao Jing” from the Han Tang 
period and “Ben Cao Gang Mu” from the Ming Dynasty5 
Accordingly, it has been hard to assign ownership and patents to 
TCM. A factor that makes patenting especially difficult is that the 
formulas and methods of ancient Chinese medicine have been passed 
down mainly in ancient books. Through these books, practitioners 
have passed down these traditions, improving prescriptions and 
methods throughout the history of TCM. 
One facet of Chinese medicine making it especially hard to patent 
is that its full efficacy is in compound prescriptions. China’s existing 
patent standard only takes into account one side of medicine, one in 
which compounds are extremely hard to classify. TCM has its own 
special characteristics and some crossover into the type of plant 
 
4 Zheng Chengsi, Challenge and Opportunity in International Intellectual Property, 
CHINESE ACADEMY OF SOCIAL SCIENCES, http://www.cass.net.cn/file/2007021587698 
.html (last visited on May 31, 2011). 
5 Zheng Yongfeng, CORPORA OF TRADITIONAL CHINESE MEDICINE PATENT 154 
(1994) (on file with author). 
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medicine generally called “alternative medicine” by the United States 
and Western countries. According to the international convention, it is 
a pre-condition for every medical patent to first describe the material 
and chemical composition of the drug. However, the ingredients in 
the compounds commonly used in Chinese medicine do not facilitate 
such concrete descriptions. TCM’s special approaches and methods 
are fundamentally different from that of Western plant-based 
medicine. In TCM, the understanding of the human body is based on 
the holistic understanding of the universe as described in Daoism, and 
the treatment of illness is based primarily on the diagnosis and 
differentiation of syndromes. Some practitioners preescribe TCM 
treatment of diseases through herbal medication, acupuncture, and qi-
gong as an “information therapy.” For example, there were noted 
advances in Chinese medicine during the Middle Ages. Emperor 
Gaozong (649–683 AD) of the Tang Dynasty (618–907 AD) 
commissioned the scholarly compilation of a materia medica in 657 
that documented 833 medicinal substances taken from stones, 
minerals, metals, plants, herbs, animals, vegetables, fruits, and cereal 
crops.6 
Accordingly, it is difficult for local TCM producers to acquire 
patents due to patent standards for medicines and TCM practitioners’ 
lack of technology and application of biochemistry. Consequently, 
there have been few patents issued for Chinese medicine under 
modern patent rules. Moreover, it is difficult to prove and evidence 
patent infringement of Chinese medicine because of the special plant 
compounds. For judges in China today, one major hurdle is how to 
identify the degree of infringement by means of the compounding of 
Chinese medicine? 
For example, Tianjin Tianshili Drugs Manufacturers Limited 
(Tianshili Company) sued Dongguan Wancheng Drug Manufacturers 
Limited for infringement of its product, the “Raise Blood Serum 
Brain Pellet.” Tianshili won the case after a 19-month trial. However, 
Tianshili received only one RMB yuan as a kind of symbolic 
compensation. The core evidence in this case was whether or not the 
different usage of Chinese angelica and rhizome causes a particular 
effect in the “Raise Blood Serum Brain Pellet.” Several experts from 
Beijing Chinese Medicine University were called on to specifically 
establish a research team to review the conflict. The major point of 
 
6 GIOVANNI MACIOCIA, THE FOUNDATIONS OF CHINESE MEDICINE 16 (1989). 
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contention in Tianshili is that a detailed infringement degree could not 
be identified by the prescription.7 
In practice, Chinese medicine has only been able to receive 
approval as a food, nutriment or food additive, rather than a 
pharmaceutical in most developed countries. Obviously, the 
difficulties in awarding patents to TCM therapies have greatly 
hindered the approval of TCMP in the international market. 
This essay will now present perspective in theory of TCMP 
conflicts and puzzles. The author has conducted research from three 
observational points: first, administrative interruption by relevant 
local officials; second, sluggish development of Chinese medicine 
innovation research; and third, neglect of the tendency of more social 
duty to global public health in the process of perfecting TCMP 
franchise rights. 
A.  Government Administration Colors the Existing Legislation 
The current legislation will likely cause one large-scale Chinese 
medicine enterprise to monopolize each specific kind of TCM. 
Although China promulgated “Chinese Medicine Variety Protection 
Rule” in 1993, it mainly stemmed from the administration of policies, 
protecting the type of Chinese medicine therapies, rather than the 
innovation of components such as compounds. Disputes occurring 
between domestic enterprises were settled by government 
administration. But obviously this legislation has no connection with 
international litigation and has no effect outside China. Moreover, it 
mainly protected the interests of producers by controlling production 
and circulation, rather than protecting consumers. 
B.  The Sluggish Development of Innovation and Research in 
Chinese Medicine 
Under Article 25 of the 2009 Chinese Patent Law no patent right 
shall be granted for the methods and diagnosis used in TCM or for the 
 
7 From 2001 to April 2008, State Intellectual Property Office processed 9571 cases of 
patent disputes and investigated 11,639 cases of patent infringement. To better protect 
intellectual property rights of patent holders, the newly revised Patent Law contains more 
detailed and specific patent protection measures. For details, see the government website 
of Intellectual Property Protection in China at http://english.ipr.gov.cn/ipr/en/info/Article 
.jsp?a_no=265466&col_no=925&dir=200902. 
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treatment of diseases and plant varieties.8 That means the application 
for TCMP has no special protection. However, TCMP standards are 
still an issue of debate in both the academic and practical fields. Some 
scholars suggest that the scope of protection for Chinese medicine 
patents should be broadened, but others support united patent 
standards. I agree with the latter approach, narrower standards, in 
general. 
The former approach, broad patent standards, emphasizes that 
TCM plant species and resources have been deeply influenced by 
humans throughout history. This approach puts fourth the idea that 
TCM led to the formation of different plant species and resources 
because of the integrated traditional production and processing 
technology like breeding, cultivating, picking, extracting, concocting 
and so on. Traditionally, Chinese doctors judge a patients disease and 
diagnose by observing the appearance of the patient, questioning the 
patient, feeling for a pulse, and then writing prescriptions based on 
experience and ancient knowledge. This is the so-called four 
diagnostic methods of Chinese medicine: “Wang, Wen, Wen, Qie.” 
Most of the ingredients in Chinese medicine are herbs. Naturally, 
TCM clinical theory consists of medicinal prescription, diagnosing 
and treating, and health care methods. It is widely known throughout 
the world that TCM is regarded as one of the main legacies of 
Chinese civilization.9 
In practice, advocates of the broad approach argue that in the long 
history of social and medical development, TCM has received special 
treatment from local government administrations, and many Chinese 
people have become dependent on TCM. Due to the lack of 
innovation, TCM practitioners have become accustomed to paying 
more attention to investing in the day-to-day practice and actually 
treating patients instead of investing in research. In general, most 
Chinese medicine enterprises show little interest or motivation in 
developing new medicine and research. One reason for this is the high 
level of technology needed for research, which requires rather high 
amounts of capital investment. 
As a result, compared with Western medicine in developed 
countries, Chinese medicine generally falls far behind the use of 
modern technologies for drug production and purification. Therefore, 
foreign pharmaceutical enterprises have been more successful in 
 
8 PRC Patent Law 2009, art. 25. 
9 XIAO SHIYING, TRADITIONAL CHINESE MEDICINE INTELLECTUAL PROTECTION 116 
(2009) (on file with author). 
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patent application in China than the Chinese domestic enterprises. In 
addition, some developed countries have also implemented special 
protection policies to compound prescription medicine in their own 
domestic markets. Advocates for a broad approach have viewed this 
as an unfair global competition, and even called it a “Chinese 
Medicine Crisis.” And some scholars have appealed to again revise 
the Chinese patent laws to give Chinese medicine special legal 
protection. The broad approach argues that TCMP scope and 
provisions should be broadened instead of generalized under patent 
law. Besides production, processing technology and forms of Chinese 
medicine should also obtain patent protection. While I do not 
advocate this approach, admittedly the idea of broadening the scope 
was created on the idea that Chinese medicine research for core 
innovation has been weak. In this sense the broad approach is 
understandable in the short term. 
The broad approach is based on the nature of patents and 
innovation. Undoubtedly, the nature of patents and innovation are the 
common rule for patent legislation all around the world. No nation 
shall award patent protection if the medicine fails to prove its own 
innovative pathological structure, and TCM is no exception. 
Therefore I prefer united patent standards for the following three 
reasons. First, we understand and respect the pathological science 
standard of medicinal plant patents. As a common rule, the medicinal 
plant in its natural state shall not be awarded a patent. Similar to most 
other countries, Chinese patent law protects Chinese medicine 
formulas and the formula dosage, rather than formula’s methods. 
With the rapid development of science and technology today, some 
international pharmaceutical companies can easily distill the therapies 
of Chinese medicine through depuration and quantification. They may 
effectively avoid the limitation of “the natural objects principle” via 
certain new technology, and make legal claims of innovation via 
pathological research.10 Most Chinese medicine enterprises have 
failed to obtain patents due to lack of high technology for pathology 
prescription. This is due to the domestic lack of technology 
innovation rather than to an unfair rule.11 We trust that it is a 
 
10 In 2010, China granted 135,000 inventions, up 5.5%. This includes 55,000 from 
abroad, representing 40.7%. Reported by State Intellectual Property Office of the P.R.C 
(SIPO), see Single Year Patent Filings Roll Over IM in China, SIPO, (Jan. 25, 2011), 
http://www.english.sipo.gov.cn/news/official/201101/t20110125-570582.html. 
11 VOLKER SCHIED, CHINESE MEDICINE IN CONTEMPORARY CHINA 116 (2002). 
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precondition for humans to learn at first before proceeding to the next 
step. 
Second, Chinese medicine in practice does not simply equal patent 
protection in law. TCMP protection in law should not go beyond 
patenting of three types: the invention, the model utility, and the 
design appearance. Though some developed countries have also 
implemented a kind of special protection policies to compound 
prescription medicine in domestic markets, this proposal is somewhat 
different. For example, in Japan and Korea, patent law requests use 
limitations. Each patent lists particular illnesses that the drug can 
treat. As a result, it is not regarded as infringement if some others use 
the same drug preparation in treating other illness. In the United 
Kingdom, France, Spain and Canada, medicine production patents 
have a kind of use definition as well. Particularly in 1997, the U.S. 
created a “Guidance for Natural Plant Mixture Drugs Application,” 
and started to accept the plant medicine compound prescription 
preparation as a kind of medical treatment. Thus all relevant actions 
have not gone beyond the scope of the patent. Accordingly, the 2010 
Chinese Patent Law has not broadened the scope to award patents 
under China’s aims of establishing innovation states in the world.12 
Third, under the WTO’s Trade Related Aspects of Intellectual 
Property Rights Agreement (TRIPS), patent regulations take effect 
not only domestically but also multinationally. It is imperative for 
China to fulfill the TRIPS promise, though China could join the 
continuing negotiation of international treaties amendments.13 If 
competition in Chinese medicine involves unfair competition or 
monopolies, it should be regulated within the scope of the unfair 
competition law and the antitrust law rather than the patent law. 
Furthermore, under the principle of national treatment in TRIPS, if 
China broadens the scope of patent protection of Chinese medicine, 
foreign medicine enterprise should be treated as an equal in Chinese 
market.14 Obviously, as a solution to strengthen the domestic 
medicine enterprise, broadening the scope of TCMP is not only 
 
12 As for TCMP protection aims, the China State Council had emphasized the 
establishment of cultivation of core technology in the Eleventh Five-Year Plan. (See The 
11th Five Year Plan, http://english.gov.cn/Special/115y_index.htm. 
13 By 2020, China plans to become a country with a comparatively high level in terms 
of the creation, utilization, protection and administration of IPRs. See Outline of the 
National Intellectual Property Strategy, June 5, 2008, http://english.gov.cn/2008-06/21 
content_1023471.htm. 
14 LONG YONGTU, WTO AND INTELLECTUAL PROPERTY 25 (2001) (on file with 
author). 
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impractical, but doesn’t align with China’s current 
internationalization strategy. 
C.  The Tendency of Increased Social Duty in Global Public Health 
Has Been Neglected in the Process of Perfecting TCMP Franchise 
Rights 
Under the principles of TRIPS, theories and knowledge of Chinese 
medicine can be used and utilized freely for public health care. And 
this same theory of public health forces every TCM production and 
method to be permitted for use in other countries. As a patent, TCM 
should have three main straits of originality, creativity, and usability. 
The scope of patent protection just focuses on the innovative 
technology, rather than knowledge itself (except traditional 
knowledge). The theories and knowledge that comprise Chinese 
medicine are viewed as fundamental innovation for humanity, and no 
one has the right to limit the public use of TCM if used for the 
promotion of human public health. 
II 
ANTICIPATION OF FUTURE DEVELOPMENT OF TCMP 
Our research discovered that in comparing Chinese medicine 
protection with other intellectual property protection forms such as 
trademark and copyright, the patent process should be more 
sophisticated and have further influence in the market. TCM is no 
exception. 
China has become an international market player under TRIPS. 
China has no choice but to continue to advocate stricter enforcement 
of IP protection. Under the non-discrimination principle of TRIPS, a 
broader protection scope on patent systems for TCM will protect the 
legal rights of foreign investors in Chinese markets as well. Similarly 
to most nations, the spirit of Chinese patents abides by a long-term 
purpose of encouraging innovation, industry and competition. Under 
such a precondition, to deal with the coming challenge of patent wars 
on the hot issue of TCMP, China has been engaged in building up a 
global pharmaceutical market. Inevitably, China shall make an effort 
to own more core medicine patents, produce national medicine patent 
pools and foster medicine research teams. Through further 
emendation of patent systems, China’s government is expected to pay 
more attention to the rapid development of Chinese medicine 
enterprises. In the meantime, it should consider keeping a balance 
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between the great efficiency in a more fierce TCMP competition and 
the legal equity for public health. 
In the long run, it is obviously an unreasonable proposal or theory 
to push China to reduce patent protection thresholds, while 
disregarding national treatment principles and the public health 
protection rule. As an alternative, China should enhance TCM 
pharmacology depuration and quantification technologies, and 
publish encouraging regulations for the technology research on TCM 
innovation. 
Above all, the author urges stabilizing high patent standards, rather 
than reducing the patent standards particular to TCM and also 
proposes that the Government create legislation in the long term. 
Thus the author suggests earnestly that relevant scholars, enterprises, 
and individuals make an effort to take detailed and positive actions as 
to the following changes in patent law. 
First, patent systems in China are experiencing a revolutionary 
reform. More detailed rules, policies, and judicial interpretations are 
expected to take effect in the coming five years. To prepare for a 
fierce global patent competition in the Chinese market, not only 
Chinese medicine researchers and enterprise, but also foreign 
investors, should learn to fully utilize updated Chinese TCMP 
measures and the timely amendment, including the utilization of the 
China TCM Patent Database.15 
Similar to the majority of countries’ medicine patent systems, 
China adheres to the patent principle of first application. Accordingly, 
before entering the medicine market in China, the primary action shall 
be to apply for patent protection promptly, or to obtain China patents 
through PCT protection. The above suggestion is merely a basic step 
towards protecting global interests for every Chinese medicine 
investor. As for legal risks in the Chinese medicine market, these 
risks involve; Chinese medicine market access, the possibility of 
similar plants increasing competition in medicine prices, and the 
ability to directly obtain patent protection after getting patents from 
other countries or international associations and so on. 
Secondly, the author suggests that Chinese domestic enterprises 
enhance the innovation of TCM core technologies in biochemistry. 
This may be done via cooperation with developed nations under an 
international coordination mechanism. For example, using the same 
 
15 For detailed information on the China TCM Patent Database, see its formal website 
at http://chmp.cnipr.cn/englishversion/login/index.asp (created and maintained by SIPO 
beginning in August, 2001). 
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technology, China’s government should look to assist the research of 
illnesses, encouraging others to produce anticancer and AIDS 
medicines, and supporting multinational cooperation. As mentioned 
above, the general superiority and advantages of a Chinese medicine 
enterprise are China’s possession of the original market and a rich 
clinical history. But as explained before, China has a history of 
deficiency in research of pathology, high technology for purification, 
and quantification. For the proposal of TCMP promotion in the new 
era, China should urge the launch of more programs of multinational 
cooperation and workshops between Chinese medicine enterprises 
and Western medicine laboratories. Such actions shall definitely 
benefit patent internationalization of Chinese medicine core 
technologies. 
Third, strengthening the protection of traditional knowledge is an 
alternative solution as a complement to patents for TCM. The author 
ponders that protecting TCM under traditional knowledge protection 
systems should be reasonable, though still may be impractical in 
China today. For example, as to the increased TCMP applications 
from multinational companies in Chinese markets which is triggering 
a number of disputes with the domestic Chinese medicine 
practitioners mentioned above, super court should draft a judicatory 
explanation that China patent implication the application should 
indicate the original source of medicine under the Convention on 
Biological Diversity. In fact, the E.U. has a practice of including such 
regulations that one should indicate the source information when 
applying for bio-technology inventions with regard to plant and 
animal materials. It is basic to respect traditional culture and holder’s 
interests in the view of traditional knowledge. 
In the end, it is imperative that China play an influential role in 
intellectual property protection in the process of her economic 
development. The author believes that the establishment of TCMP 
systems for both domestic and foreign researchers and enterprises, 
featuring competitive-neutral standards as a practical mechanism, 
shall be a requirement for China to make the grade in a developed 
Chinese medicine market in the next decade. 
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